Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Diseases 1

Interventions

Brentuximab Vedotin 20 Rituximab 10 pirtobrutinib 7 dacetuzumab 7 Doxorubicin 6 ruxolitinib 5 Vincristine 5 Prednisone 5 Lenalidomide 5 Cyclophosphamide 5 ponatinib 4 Imatinib Mesylate 4 Dexamethasone 4 Bendamustine Hydrochloride 4 Azacitidine 4 nilotinib 3 lintuzumab 3 Bortezomib 3 vosaroxin 2 venetoclax 2 spartalizumab 2 pomalidomide 2 ibrutinib 2 Rifampin 2 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2 KW-2478 2 Ifosfamide 2 Gemcitabine 2 Etoposide 2 Dacarbazine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hematologic Diseases × CHR 2845 × Clear all

NCT00820508 2011-11-28

CHR-2845-001

Chroma Therapeutics

Phase 1 Completed

Hematologic Diseases

Data powered by HemOnc (CC BY 4.0) Colophon ⚡